TVM VI LSV Beteiligungsgesellschaft mbH, based in Munich, operates as an investment holding company for limited partnerships. Its primary purpose is the management and divestment of interests in TVM VI Life Science Ventures GmbH & Co. KG. This target entity invests in companies with high growth potential within the healthcare and biotechnology sectors. The geographical focus of these investments spans Germany, the USA, and selected European countries.
Beteiligung an Kommanditgesellschaften - insbesondere an der TVM VI Life Science Ventures GmbH & Co. KG - deren Gegenstand Erwerb, Verwaltung und Veräußerung von Beteiligungen an Gesellschaften mit hohem Wachstumspotential in den Bereichen Gesundheitswesen und Biotechnologie, insbesondere in Deutschland, USA sowie in ausgewählten europäischen Ländern ist.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) München Local Court, HRB 154643 (as of 19 November 2026)
| Name | Type | City |
|---|---|---|
| Josef Moosholzer | Geschäftsführer(in) | München |
Source: German Commercial Register (Handelsregister) München Local Court, HRB 154643 (as of 19 November 2026)
| Date | Event Type | Event |
|---|---|---|
| 03.01.2014 | Business Address Change | Ottostr. 4, 80333 München |
| 14.06.2010 | Business Address Change | Maximilianstr. 35C, 80539 München |
| 26.05.2010 | Business Address Registered | Maximilianstr. 35, 80539 München |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 15.11.2004 | Share Capital Set | — | 25.000 € |
Source: German Commercial Register (Handelsregister) München Local Court, HRB 154643 (as of 19 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | Gross profit€39.1K2 | -€2,689,277 | €36,548,908 | — |
| 2024 | Gross profit€1.4K2 | -€2,556,956 | €33,844,144 | — |
| 2023 | Gross profit€02 | -€1,935,597 | €31,330,513 | — |
| 2022 | — | -€2,326,414 | €29,855,559 | — |
| 2021 | — | -€1,905,141 | €27,646,573 | — |
| 2020 | — | -€290,516 | €25,612,561 | — |
| 2019 | — | -€3,645,661 | €29,162,471 | — |
| 2018 | — | -€2,013,941 | €28,149,906 | — |
| 2017 | — | €878,443 | €26,399,951 | — |
| 2016 | — | -€1,735,870 | €26,797,416 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Gross profit under § 276 HGB: revenue less the cost of materials or cost of sales. Small and medium-sized companies may combine these items; revenue itself is then not disclosed and exceeds gross profit.
Source: German Company Register (Unternehmensregister) · Annual accounts
Sign in to download data
Source: German Commercial Register (Handelsregister) München Local Court, HRB 154643 (as of 19 November 2026)
Interpeer gUG (haftungsbeschränkt)
Greifenberg · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
PRODEFION GmbH
Berlin · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
TETEC Tissue Engineering Technologies AG
Reutlingen · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen